Antitumor Activity Of BRAF Inhibitor Vemurafenib In Preclinical ...

Trang chủ » H-2941-72 » Antitumor Activity Of BRAF Inhibitor Vemurafenib In Preclinical ...

Có thể bạn quan tâm

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon 600 promote catalytic activity and are associated with 8% of all human (solid) tumors, including 8% to 10% of colorectal cancers (CRC). Here, we report the preclinical characterization of vemurafenib (RG7204; PLX4032; RO5185426), a first-in-class, specific small molecule inhibitor of BRAF(V600E) in BRAF-mutated CRC cell lines and tumor xenograft models. As a single agent, vemurafenib shows dose-dependent inhibition of ERK and MEK phosphorylation, thereby arresting cell proliferation in BRAF(V600)-expressing cell lines and inhibiting tumor growth in BRAF(V600E) bearing xenograft models. Because vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic CRC, we therefore explored a range of combination therapies, with both standard agents and targeted inhibitors in preclinical xenograft models. In a BRAF-mutant CRC xenograft model with de novo resistance to vemurafenib (RKO), tumor growth inhibition by vemurafenib was enhanced by combining with an AKT inhibitor (MK-2206). The addition of vemurafenib to capecitabine and/or bevacizumab, cetuximab and/or irinotecan, or erlotinib resulted in increased antitumor activity and improved survival in xenograft models. Together, our findings suggest that the administration of vemurafenib in combination with standard-of-care or novel targeted therapies may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mutation.

PubMed Disclaimer

Comment in

  • Gastrointestinal cancer: Combine and conquer. Kirk R. Kirk R. Nat Rev Clin Oncol. 2012 Jan 17;9(2):67. doi: 10.1038/nrclinonc.2011.215. Nat Rev Clin Oncol. 2012. PMID: 22249442 No abstract available.

Publication types

  • Research Support, Non-U.S. Gov't Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

MeSH terms

  • Animals Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Antibodies, Monoclonal / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Antibodies, Monoclonal, Humanized / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Area Under Curve Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Bevacizumab Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Blotting, Western Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Camptothecin / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Camptothecin / analogs & derivatives Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Capecitabine Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cell Line, Tumor Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cell Proliferation / drug effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cetuximab Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Colorectal Neoplasms / drug therapy* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Colorectal Neoplasms / genetics Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Colorectal Neoplasms / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Deoxycytidine / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Deoxycytidine / analogs & derivatives Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Dose-Response Relationship, Drug Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Drug Resistance, Neoplasm / drug effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Erlotinib Hydrochloride Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Fluorouracil / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Fluorouracil / analogs & derivatives Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • HCT116 Cells Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • HT29 Cells Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Humans Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Indoles / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Indoles / pharmacokinetics Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Indoles / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Irinotecan Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Kaplan-Meier Estimate Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mice Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mice, Nude Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mitogen-Activated Protein Kinases / metabolism Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mutation Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Phosphorylation / drug effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Proto-Oncogene Proteins B-raf / genetics Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Proto-Oncogene Proteins B-raf / metabolism Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Quinazolines / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Sulfonamides / administration & dosage Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Sulfonamides / pharmacokinetics Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Sulfonamides / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Vemurafenib Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Xenograft Model Antitumor Assays* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Substances

  • Antibodies, Monoclonal Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Antibodies, Monoclonal, Humanized Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Indoles Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Quinazolines Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Sulfonamides Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Deoxycytidine Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Vemurafenib Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Bevacizumab Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Capecitabine Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Irinotecan Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Erlotinib Hydrochloride Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • BRAF protein, human Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Proto-Oncogene Proteins B-raf Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mitogen-Activated Protein Kinases Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cetuximab Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Fluorouracil Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Camptothecin Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Grants and funding

  • KL2 TR000370/TR/NCATS NIH HHS/United States

LinkOut - more resources

  • Full Text Sources

    • Silverchair Information Systems

  • Other Literature Sources

    • The Lens - Patent Citations Database

  • Medical

    • MedlinePlus Health Information

  • Research Materials

    • NCI CPTC Antibody Characterization Program

  • Miscellaneous

    • NCI CPTAC Assay Portal

Từ khóa » H-2941-72